DAFNA Capital Management LLC Reduces Position in Gossamer Bio, Inc. $GOSS

Key Points

• DAFNA Capital Management LLC has reduced its stake in Gossamer Bio, Inc. by 35.6%, owning approximately 0.40% of the company after selling over 500,000 shares.
• Institutional investors dominate Gossamer Bio's shareholding, with hedge funds owning 81.23% of the stock, suggesting strong confidence in the company's future.
• Gossamer Bio reported better-than-expected earnings of ($0.17) per share and revenue of $11.49 million, significantly surpassing analysts' expectations of $4.12 million for the quarter.

DAFNA Capital Management LLC decreased its position in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 35.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 907,854 shares of the company's stock after selling 501,408 shares during the period. DAFNA Capital Management LLC owned 0.40% of Gossamer Bio worth $999,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Graham Capital Management L.P. acquired a new stake in shares of Gossamer Bio in the 4th quarter valued at $32,000. Virtu Financial LLC acquired a new stake in shares of Gossamer Bio during the 1st quarter valued at approximately $38,000. Fullcircle Wealth LLC acquired a new stake in shares of Gossamer Bio during the 4th quarter valued at approximately $43,000. Invesco Ltd. purchased a new position in shares of Gossamer Bio during the 1st quarter worth approximately $48,000. Finally, Velan Capital Investment Management LP purchased a new stake in Gossamer Bio in the 4th quarter worth approximately $68,000. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Stock Down 0.4%

Shares of GOSS stock traded down $0.01 during trading hours on Wednesday, hitting $2.58. 3,288,755 shares of the company were exchanged, compared to its average volume of 2,055,139. The business has a 50 day moving average of $1.81 and a two-hundred day moving average of $1.37. The company has a current ratio of 4.40, a quick ratio of 4.40 and a debt-to-equity ratio of 6.70. Gossamer Bio, Inc. has a 52 week low of $0.66 and a 52 week high of $2.71. The company has a market capitalization of $586.64 million, a PE ratio of -4.16 and a beta of 1.95.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.01. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%. The firm had revenue of $11.49 million during the quarter, compared to analysts' expectations of $4.12 million. Analysts anticipate that Gossamer Bio, Inc. will post -0.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on GOSS. Wall Street Zen cut shares of Gossamer Bio from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Wedbush upped their target price on shares of Gossamer Bio from $4.00 to $5.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 6th. Scotiabank began coverage on shares of Gossamer Bio in a report on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 price objective for the company. Finally, The Goldman Sachs Group raised their price objective on shares of Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Friday, May 16th. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Gossamer Bio has an average rating of "Buy" and an average price target of $8.50.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.